Transforming growth factor-β promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway (Q38926353)

7 September 2017

Transforming growth factor-β promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway (English)

1 reference

7 September 2017

1 reference

M K Siu

1

1 reference

7 September 2017

Y-C Tsai

2

1 reference

7 September 2017

Y-S Chang

3

1 reference

7 September 2017

J J Yin

4

1 reference

7 September 2017

F Suau

5

1 reference

7 September 2017

W-Y Chen

6

1 reference

7 September 2017

Y-N Liu

7

1 reference

7 September 2017

language of work or name

English

0 references

publication date

22 December 2014

1 reference

7 September 2017

1 reference

7 September 2017

34

1 reference

7 September 2017

4767-4776

1 reference

7 September 2017

36

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2014.414

7 September 2017

0 references

cites work

TGFbeta signalling: a complex web in cancer progression

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Transforming growth factor-beta in benign and malignant prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

The TGF-beta paradox in human cancer: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Smad-dependent and Smad-independent pathways in TGF-beta family signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

mTOR: from growth signal integration to cancer, diabetes and ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Crosstalk between TGF-β signaling and the microRNA machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Critical and reciprocal regulation of KLF4 and SLUG in transforming growth factor β-initiated prostate cancer epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Integrative genomic profiling of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

The antiapoptotic function of miR-96 in prostate cancer by inhibition of FOXO1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

v-ras genes from Harvey and BALB murine sarcoma viruses can act as initiators of two-stage mouse skin carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Gatifloxacin induces S and G2-phase cell cycle arrest in pancreatic cancer cells via p21/p27/p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Re-oxygenation causes hypoxic tumor regression through restoration of p53 wild-type conformation and post-translational modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Functional p53 determines docetaxel sensitivity in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

MicroRNAs--the micro steering wheel of tumour metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.414

Targeting bone metastatic cancer: Role of the mTOR pathway

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25531317

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Profiling of signaling molecules in four different human prostate carcinoma cell lines before and after induction of apoptosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25531317

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/ONC.2014.414

1 reference

Dimensions Publication ID

7 September 2017

1018853669

0 references

Fatcat ID

release_5h7osprbjzgt5gr2baxzjngidu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5h7osprbjzgt5gr2baxzjngidu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference